Celon Pharma SA (CLN) - Total Assets
Based on the latest financial reports, Celon Pharma SA (CLN) holds total assets worth zł457.46 Million PLN (≈ $125.90 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Celon Pharma SA's book value for net asset value and shareholders' equity analysis.
Celon Pharma SA - Total Assets Trend (2012–2025)
This chart illustrates how Celon Pharma SA's total assets have evolved over time, based on quarterly financial data.
Celon Pharma SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Celon Pharma SA's total assets of zł457.46 Million consist of 0.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0.0% |
| Accounts Receivable | zł0.00 | 0.0% |
| Inventory | zł0.00 | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł0.00 | 0.0% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Celon Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Celon Pharma SA worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celon Pharma SA's current assets represent 0.0% of total assets in 2025, a decrease from 25.2% in 2012.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 8.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Celon Pharma SA Competitors by Total Assets
Key competitors of Celon Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Cipla Limited
NSE:CIPLA
|
India | Rs401.64 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.22 Trillion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥11.40 Billion |
Celon Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 2.67 | 1.69 |
| Quick Ratio | 1.07 | 2.30 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł28.41 Million | zł120.99 Million | zł48.35 Million |
Celon Pharma SA - Advanced Valuation Insights
This section examines the relationship between Celon Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.16 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -15.9% |
| Total Assets | zł457.46 Million |
| Market Capitalization | $312.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Celon Pharma SA's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Celon Pharma SA's assets decreased by 15.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celon Pharma SA (2012–2025)
The table below shows the annual total assets of Celon Pharma SA from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł457.46 Million ≈ $125.90 Million |
-15.88% |
| 2024-12-31 | zł543.79 Million ≈ $149.66 Million |
-4.48% |
| 2023-12-31 | zł569.31 Million ≈ $156.68 Million |
-6.51% |
| 2022-12-31 | zł608.93 Million ≈ $167.59 Million |
-13.89% |
| 2021-12-31 | zł707.14 Million ≈ $194.61 Million |
+0.50% |
| 2020-12-31 | zł703.64 Million ≈ $193.65 Million |
+18.99% |
| 2019-12-31 | zł591.35 Million ≈ $162.75 Million |
+4.91% |
| 2018-12-31 | zł563.67 Million ≈ $155.13 Million |
+7.36% |
| 2017-12-31 | zł525.05 Million ≈ $144.50 Million |
+13.08% |
| 2016-12-31 | zł464.32 Million ≈ $127.79 Million |
+175.91% |
| 2015-12-31 | zł168.29 Million ≈ $46.32 Million |
+59.61% |
| 2014-12-31 | zł105.44 Million ≈ $29.02 Million |
+27.66% |
| 2013-12-31 | zł82.59 Million ≈ $22.73 Million |
+18.33% |
| 2012-12-31 | zł69.80 Million ≈ $19.21 Million |
-- |
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.